Elicea tablets 10mg, no. 56
Expiration Date: 11/2025
Russian Pharmacy name:
Элицея таблетки 10мг, №56
Depression, panic disorder (including agoraphobia).
Inside, 1 time per day, regardless of food intake.
Depressive episodes. The recommended dose is 10 mg / day. Depending on the individual response of the patient, the dose can be increased to a maximum of 20 mg / day.
The antidepressant effect develops 2Ц4 weeks after the start of treatment. After the disappearance of the symptoms of depression, it is necessary to continue therapy for at least 6 months to consolidate the effect obtained.
To discontinue escitalopram therapy, it is necessary to gradually reduce the dose over 1Ц2 weeks in order to reduce the risk of withdrawal syndrome.
Panic disorder (including agoraphobia). 5 mg / day for the 1st week, then 10Ц20 mg / day. The maximum daily dose is 20 mg.
The maximum therapeutic effect is achieved approximately 3 months after the start of treatment.
Elderly patients (over 65 years old). The recommended dose is 5 mg / day, the maximum daily dose is 10 mg / day.
Renal dysfunction. With mild or moderate renal failure (Cl creatinine more than 30 ml / min), dose adjustment is not required. In severe renal failure (Cl creatinine less than 30 ml / min), the drug should be prescribed with caution.
Liver dysfunction. In case of impaired liver function, the initial dose is 5 mg / day for 2 weeks. Depending on the individual response of the patient, the dose may be increased to 10 mg / day. In severe liver dysfunction, a slower dose titration is recommended.
Reduced activity of the isoenzyme CYP2C19. The recommended initial dose for the first 2 weeks is 5 mg / day, depending on the patient's individual response, the dose may be increased to 10 mg / day.
| Film-coated tablets | 1 tab. |
| core | |
| active substance: | |
| escitalopram oxalate | 6.39 / 12.78 / 25.56 mg |
| (equivalent to escitalopram 5/10/20 mg) | |
| excipients: lactose monohydrate - 53.61 / 107.22 / 214.44 mg; crospovidone - 3.75 / 7.5 / 15 mg; povidone K30 - 0.375 / 0.75 / 1.5 mg; MCC - 7.5 / 15/30 mg; pregelatinized starch - 1.875 / 3.75 / 7.5 mg; magnesium stearate - 1.5 / 3/6 mg | |
| film shell: Opadry white 33G28707 (consists of a mixture of hypromellose 6cP (40%), titanium dioxide (24%), lactose monohydrate (22%), macrogol 3000 (8%) and triacetin (6%) - 1.875 / 3.75 / 7.5 mg |
hypersensitivity to escitalopram and other components of the drug;
simultaneous use with MAO inhibitors;
simultaneous use with pimozide;
galactosemia, lactase deficiency, glucose-galactose malabsorption syndrome;
pregnancy;
breastfeeding period;
age up to 18 years (efficacy and safety have not been studied).
With care: pharmacologically uncontrolled epilepsy, mania / hypomania in history, diabetes mellitus, depression with suicidal attempts, old age, cirrhosis of the liver, chronic renal failure (Cl creatinine less than 30 ml / min), ischemic heart disease, tendency to bleed; simultaneous use of drugs that can cause hyponatremia, lowering the threshold of convulsive readiness, anticoagulants or drugs that affect platelet aggregation, alcohol, lithium, St. John's wort, tryptophan, drugs metabolized with the participation of the CYP2C19 isoenzyme system; simultaneous use of electroconvulsive therapy (ECT), age 18-24 years (due to the risk of developing suicidal behavior).